文献速递眼底病与葡萄膜炎

推进近视管理:微生物群靶向干预的治疗潜力

Advancing Myopia Management: The Therapeutic Potential of Microbiota-Targeted Interventions.
PubMed 文献 · Am J Ophthalmol · 2025-07-09

本研究采用16S rRNA测序分析高度近视组与正常对照组眼表微生物群,发现两组微生物多样性存在显著差异,酒酒球菌(L. vini)在正常对照组富集。体内外实验证实酒酒球菌可下调形觉剥夺近视小鼠眼表炎症因子IL-6和TNF-α,抑制巩膜重塑,减轻近视表型变化。

要点

  • 高度近视组与正常对照组眼表微生物多样性存在显著差异。
  • 酒酒球菌在正常对照组富集,可能抑制近视进展。
  • 酒酒球菌可下调形觉剥夺近视小鼠眼表IL-6和TNF-α,抑制巩膜重塑。

核心结论

  • 酒酒球菌可能通过调节眼表炎症帮助减缓近视进展。
  • 未来需采用基因组技术进一步理解微生物群靶向干预在近视管理中的机制和治疗潜力。

研究设计与样本

  • 研究采用16S rRNA测序分析高度近视组和正常对照组的眼表微生物群。
  • 研究比较了微生物多样性和组成,重点关注酒酒球菌的丰度。
  • 研究进行了相关性分析探索影响差异丰富菌种分布的潜在因素。
  • 研究通过体内和体外实验评估酒酒球菌在胶原蛋白-1合成、巩膜重塑和眼部炎症中的作用。

主要发现

  • 高度近视组与正常对照组之间微生物多样性存在显著差异。
  • 酒酒球菌在正常对照组富集,并提示具有抑制近视进展的潜力。
  • 近视个体的酒酒球菌失调可能也受父母近视背景介导。
  • 体内外实验证实酒酒球菌下调形觉剥夺近视小鼠眼表炎症标志物IL-6和TNF-α,抑制巩膜重塑,减少近视表型变化。

局限性

  • 未来需采用基因组技术进一步理解微生物群靶向干预在近视管理中的机制和治疗潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Myopia is a growing global health concern, particularly in East Asia. Recent studies suggest that ocular surface microbiota may play a key role in regulating local immune homeostasis in the eye. This study aims to investigate the relationship between ocular surface microbiota and high myopia (HM), with the goal of identifying potential microbiota targets for controlling myopia progression. METHODS: 16S rRNA sequencing was used to analyze ocular surface microbiota in HM and NC groups. Microbial diversity and composition were compared, focusing on the abundance of Lactobacillus vini (L. vini). The correlation analysis explores potential factors influencing the distribution of differentially abundant bacterial species. In vivo and in vitro experiments assessed its role in Collagen-1 synthesis, scleral remodeling, and ocular inflammation. RESULTS: Significant differences in microbial diversity were found between the HM and NC groups. L. vini was enriched in the NC group and suggested potential in inhibiting myopia progression. Dysbiosis of L. vini in myopic individuals may also be mediated by parental myopia background. In vivo and in vitro experiments further confirmed that L. vini downregulated ocular surface inflammatory markers IL-6 and TNF-α in form deprivation myopic mice, inhibited scleral remodeling, and reduced myopic phenotypic changes. CONCLUSIONS: L. vini may help mitigate myopia progression, potentially through regulating ocular surface inflammation. Future studies using genomic techniques are needed to further understand the mechanisms and therapeutic potential of microbiota-targeted interventions in myopia management.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Zhao L, Xie Y, Chen W, et al. Advancing Myopia Management: The Therapeutic Potential of Microbiota-Targeted Interventions. Am J Ophthalmol. 2025. PMID: 40645551. doi:10.1016/j.ajo.2025.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。